|Articles|November 1, 2003

MATTER SETTLED

Cool Laser Optics (CLO) Inc., owner of patents regarding skin cooling, has reached an agreement with Lumenis Inc., a laser manufacturer, over issues regarding alleged infringement of certain CLO patents.

Newsletter

Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.

Subscribe

Related Content

AAD Pediatric AD Guidelines Back Roflumilast, Ruxolitinib, Tapinarof

ByShannon Heaning, Content Associate

August 4th 2026

Breakout Bulletin: July 27-July 31

ByShannon Heaning, Content Associate

August 3rd 2026

Elevate-Derm Faculty Highlight Expanding Role of Oral JAK Inhibitors in Pediatric Dermatology

ByShannon Heaning, Content Associate

July 31st 2026

RAD 2026: Experts Weigh In on AD Pipeline, Pediatric Care, and Personalized Treatment

ByKaitlyn Bader, Assistant Managing Editor

July 30th 2026

Don't Be Rash: How To Care For Newborn Skin, Cord, and Diaper Area

ByAndrew C. Krakowski, MD,Raegan D. Hunt, MD, PhD,Kaitlyn Bader, Assistant Managing Editor

July 28th 2026

Latest CME

Video

Clear Skin, Clear Mind: Integrating Mental Health into Psoriasis Care

John Koo, MD; T.J. Chao, MPAS, PA-C

Adaptive Learning

Medical Crossfire®: Navigating Chronic GVHD Prophylaxis and Treatment – Targeted Strategies to Elevate Patient Outcomes

Corey Cutler, MD, MPH, FRCP(C); Amin M. Alousi, MD; Mehdi Hamadani, MD; Anna Sureda, MD, PhD

MATTER SETTLED

Related Content

AAD Pediatric AD Guidelines Back Roflumilast, Ruxolitinib, Tapinarof

Breakout Bulletin: July 27-July 31

Elevate-Derm Faculty Highlight Expanding Role of Oral JAK Inhibitors in Pediatric Dermatology

RAD 2026: Experts Weigh In on AD Pipeline, Pediatric Care, and Personalized Treatment

Don't Be Rash: How To Care For Newborn Skin, Cord, and Diaper Area

Latest CME

Clear Skin, Clear Mind: Integrating Mental Health into Psoriasis Care

Medical Crossfire®: Navigating Chronic GVHD Prophylaxis and Treatment – Targeted Strategies to Elevate Patient Outcomes

Trending on Dermatology Times

AAD Pediatric AD Guidelines Back Roflumilast, Ruxolitinib, Tapinarof

ICYMI: EU Approves Upadacitinib for Severe Alopecia as US Review Remains Pending

Extended-Release Oral Minoxidil Shows Rapid Onset Of Hair Growth In Female Androgenetic Alopecia

FDA Approves RP1 Plus Nivolumab for Advanced Melanoma

Interim Trial Results and Preclinical Data Highlight Potential of ABS-201 in Androgenetic Alopecia